Table 2.
Initial presentation by stage.
| Parameter | Total N = 433 | Stage 0 N = 89 | Stage I N = 81 | Stage II N = 79 | Stage IIIA N = 79 | Stage IIIB N = 105 | p-Value | |
|---|---|---|---|---|---|---|---|---|
| Age (years) | Mean ± SD | 10.7 ± 0.1 | 9.7 ± 0.2 | 10.9 ± 0.2 | 10.5 ± 0.2 | 11.3 ± 0.2 | 11.1 ± 0.2 | <0.0001a |
| Hormonal status | Intact female | 324 (74.8%) | 76 (85.4%) | 56 (69.1%) | 60 (75.9%) | 53 (67.1%) | 79 (75.5%) | NS 0.055b |
| Neutered female | 109 (25.2%) | 13 (14.6%) | 25 (30.9%) | 19 (24.1%) | 26 (32.9%) | 26 (24.5%) | ||
| Contraception | No or unknown | 405 (93.6%) | 81 (91.0%) | 71 (87.7%) | 76 (96.2%) | 76 (96.2%) | 101 (96.1%) | NS 0.070c |
| Yes | 28 (6.4%) | 8 (9.0%) | 10 (12.3%) | 3 (3.8%) | 3 (3.8%) | 4 (3.9%) | ||
| Multicentricity | Yes | 59 (13.6%) | 7 (7.9%) | 14 (17.3%) | 10 (12.7%) | 14 (17.7%) | 14 (13.3%) | NS 0.103b |
| No | 374 (86.4%) | 82 (92.1%) | 67 (82.7%) | 69 (87.3%) | 65 (82.3%) | 91 (86.7%) | ||
| Locationd | M1–M2 | 68 (17.5%) | 18 (23.4%) | 17 (23.9%) | 12 (16.0%) | 11 (15.3%) | 10 (10.8%) | NS 0.181b |
| M3–M5 | 309 (79.6%) | 59 (76.6%) | 51 (71.8%) | 62 (82.7%) | 58 (80.6%) | 79 (84.9%) | ||
| Thoraco-abdominal | 11 (2.9%) | 0 (0%) | 3 (4.2%) | 1 (1.3%) | 3 (4.1%) | 4 (4.3%) | ||
| Inflammation | Moderate to severe | 185 (42.7%) | 19 (21.3%) | 24 (29.6%) | 33 (41.8%) | 46 (58.2%) | 63 (60.0%) | <0.0001b |
| Absent to mild | 248 (57.3%) | 70 (78.7%) | 57 (70.4%) | 46 (58.2%) | 33 (41.8%) | 42 (40.0%) | ||
| Central necrosis | Yes | 326 (75.3%) | 70 (78.7%) | 56 (69.1%) | 68 (86.1%) | 54 (68.4%) | 78 (74.3%) | NS 0.056b |
| No | 107 (24.7%) | 19 (21.3%) | 25 (30.9%) | 11 (13.9%) | 25 (31.6%) | 27 (25.7%) | ||
| Margins | Negative | 251 (58.0%) | 62 (69.7%) | 69 (85.2%) | 47 (59.5%) | 39 (49.4%) | 34 (32.4%) | <0.0001b |
| Positive | 182 (42.0%) | 27 (31.3%) | 12 (14.8%) | 32 (40.5%) | 40 (50.6%) | 71 (67.6%) | ||
| Histological grade | I | 78 (18.0%) | 59 (66.3%) | 16 (19.8%) | 1 (1.3%) | 1 (1.3%) | 1 (1.0%) | <0.0001b |
| II | 130 (30.0%) | 26 (29.2%) | 28 (34.6%) | 24 (30.4%) | 29 (36.7%) | 23 (21.9%) | ||
| III | 225 (52.0%) | 4 (4.5%) | 37 (45.7%) | 54 (68.3%) | 49 (62.0%) | 81 (77.1%) | ||
| ER | Mean index (%) ± SD | 7.3 ± 13.1 | 11.7 ± 10.8 | 6.2 ± 11.8 | 5.6 ± 13.2 | 7.7 ± 15.0 | 5.3 ± 13.6 | 0.005a |
| ER– (<10%) | 338 (78.1%) | 50 (56.2%) | 64 (79.0%) | 69 (87.3%) | 62 (78.5%) | 93 (88.6%) | <0.0001b | |
| ER+ (≥10%) | 95 (21.9%) | 39 (43.8%) | 17 (21.0%) | 10 (12.7%) | 17 (21.5%) | 12 (11.4%) | ||
| PR | Mean index (%) ± SD | 7.2 ± 14.9 | 14.0 ± 12.7 | 10.0 ± 21.2 | 5.2 ± 13.0 | 4.2 ± 13.2 | 3.4 ± 10.3 | <0.0001a |
| PR– (<10%) | 348 (80.4%) | 44 (49.4%) | 65 (80.2%) | 71 (89.9%) | 71 (89.9%) | 97 (92.4%) | <0.0001b | |
| PR+ (≥10%) | 85 (19.6%) | 45 (50.6%) | 16 (19.8%) | 8 (10.1%) | 8 (10.1%) | 8 (7.6%) | ||
| HER2 | Score 0 | 293 (67.7%) | 50 (56.2%) | 62 (76.5%) | 54 (68.4%) | 54 (68.3%) | 73 (69.5%) | NS 0.089b |
| Score 1+ | 108 (24.9%) | 33 (37.1%) | 15 (18.5%) | 16 (20.3%) | 21 (26.6%) | 23 (21.9%) | ||
| Score 2+ | 32 (7.4%) | 6 (6.7%) | 4 (5.0%) | 9 (11.3%) | 4 (4.1%) | 9 (8.6%) | ||
| Immunophenotype | Luminal | 140 (32.3%) | 58 (65.2%) | 28 (34.6%) | 15 (19.0%) | 22 (27.8%) | 17 (16.2%) | <0.0001b |
| Triple-negative | 293 (67.7%) | 31 (34.8%) | 53 (65.4%) | 64 (81.0%) | 57 (72.2%) | 88 (83.8%) | ||
| Ki-67 | Mean index (%) ± SD | 33.5 ± 17.1 | 23.4 ± 10.8 | 33.3 ± 16.3 | 30.8 ± 16.3 | 39.0 ± 17.7 | 40.2 ± 19.5 | <0.0001a |
| Ki-67 <20% | 94 (21.7%) | 34 (38.2%) | 19 (23.4%) | 17 (21.5%) | 10 (12.6%) | 14 (13.3%) | 0.0002b | |
| Ki-67 ≥20% | 339 (78.3%) | 55 (61.8%) | 62 (76.6%) | 62 (78.5%) | 69 (87.4%) | 91 (86.7%) | ||
| CK5/6e | CK5/6– (<10%) | 117 (34.0%) | undetermined | 24 (29.6%) | 33 (41.8%) | 22 (27.8%) | 38 (36.2%) | <0.0001b |
| CK5/6+ (≥10%) | 227 (66.0%) | undetermined | 57 (70.4%) | 46 (58.2%) | 57 (72.2%) | 67 (63.8%) | ||
| EGFRe | EGFR– (<10%) | 160 (46.5%) | undetermined | 30 (37.0%) | 37 (46.8%) | 37 (46.8%) | 56 (53.3%) | <0.0001b |
| EGFR+ (≥10%) | 184 (53.5%) | undetermined | 51 (63.0%) | 42 (53.2%) | 42 (53.2%) | 49 (46.7%) |
a
Analysis of variance.
b
Chi-square test.
c
Fisher's exact test.
d
On a total of 388 cases (45 others from unknown location).
e
Only available for stage I–IIIB (invasive) carcinomas (N = 344).
NS, Not Significant; SD, standard deviation.